References:
Masquelier,
J. Plant extract with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice,
Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food
Chem. Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity
of Aquila Pharmacol-Toxicologica Report, 1971.
Laparra, J., et al., Acta Therapeutica,
4:233, 1978.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J.
Proanthocyanidin content in vegetable extracts to be used in the preparation of
medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
Kidd, P.M. Phosphatidylserine:
the nutrient that accelerates all brain functions and counters Alzheimer’s
disease: Keats Pub. 1998.
Cenacchi T, et al. Cognitive decline in the elderly:
A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine
administration. Aging, 5: 123–133, 1993.
Maggioni M, Picotti GB, Bondiolotti
GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive
disorders. Acta Psychiatr Scand. 81: 265–270, 1990.
Brambilla, F., Maggioni,
M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear
cells of elderly depressed patients—effects of phosphatidylserine therapy.
Neuropsychobiology, 34: 18–21, 1996.
Monteleone P., Maj M., Beinat L.,
Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of
the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm, 43: 385–388, 1992.
Cenacchi T, et al., “Cognitive
decline in the elderly: A double-blind, placebo-controlled multicenter study on
efficacy of phosphatidylserine administration.” Aging, 5, 123-133, 1993
Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind
study with phosphatidylserine (PS) in parkinsonian patients with senile dementia
of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
Le
Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, F.A.
A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba
for dementia. Journal of the Amer Med Assoc, 278 (16):1327-32, 1997.
and
seeds from 
Dr.
Masquelier’s unequaled manufacturing process has been conducted for half
a century at the very same facilities in France, and under the control of French
Pharmaceutical inspection. These time-proven standards serve as a reliable assurance
of the quality, consistency, bioavailability and safety of Flavay ™. 
Everyone,
from the very young to the elderly. Flavay ™ has no known contraindications
(conditions under which it should not be used). Flavay ™ is completely
safe and nontoxic. In fact, clinical trials have been conducted in
which pregnant women (troubled by varicose veins and other circulatory problems
in the legs) safely used Flavay ™. Flavay ™ may enhance the anticoagulant
effects of anticoagulant drugs (such as Coumadin or heparin). Notify your physician
if you are taking anticoagulant drugs, as a blood test may indicate to your physician
that the drug dose may be reduced if Flavay ™ or Flavay Plus ™ is being
consumed. This is because Flavay ™ has been shown to normalize the reactivity
("stickiness") of blood platelets. 
Flavay
Plus ™ includes phosphatidyl serine, derived from soy lecithin, which has
been proven safe in standard toxicology tests. From the large number of human
studies conducted, phosphatidyl serine has developed a flawless safety record
and proven compatible with a wide array of medications.
CLICK
ON BUTTON TO RECEIVE A FREE 
